Use of a novel debriding agent based on collagenase and hyaluronate lyase to enhance angiogenesis, stimulate healing, and reduce pain in chronic cutaneous wounds.

BACKGROUND

Chronic wounds pose a serious health challenge, reducing patient and caregiver quality of life and demanding substantial resources. Debridement is essential for healing, with collagenase being one of the most widely used agents.

OBJECTIVE

To determine the clinical efficacy and safety of a novel bioactive topical formulation combining collagenases G and H, and hyaluronate lyase, for treating chronic ulcers.

MATERIAL AND

METHODS

A prospective 2-arm longitudinal comparative interventional study was conducted. Twenty-five patients were allocated into 2 groups and treated for 21 days with conventional dressing. The intervention group (n = 17) additionally received the novel formulation, whereas the control group (n = 8) did not. Epithelialization, angiogenesis, and wound closure were evaluated, as well as patient satisfaction and product safety in terms of pain and adverse effects.

RESULTS

A significantly greater reduction in wound area was observed in the intervention group (baseline median area of 40.0 cm² vs final median area of 16.0 cm²; 60% reduction; P = .0004) compared with controls (baseline median area of 36.0 cm² vs final median area of 24.0 cm²; 33.3% reduction; P = .08). Histological analysis revealed significantly increased angiogenesis in the intervention group (P = .046). The product was rated as highly satisfactory by both physicians and patients in its use and results.

CONCLUSION

The novel formulation demonstrated efficacy in promoting vascularization and reducing the wound area, indicating that it could be a valuable tool for treating chronic ulcers, with significant potential for promoting faster and more effective healing than conventional options.